Comparative analysis of chronic rhinitis patient profiles during autumn pollen season between grassland and non-grassland cities in North China

Xu Xu1,2,3†, Long Qin4†, Lei Ren3, Chengshuo Wang1,2, Yuan Zhang1,2,3* and Luo Zhang1,2,3*

Abstract

Background: The symptoms of patients with respiratory disease are influenced by local environmental factors. The incidence of allergic rhinitis in grassland areas was significantly higher than that in non-grassland areas. We aimed to compare the profiles of chronic rhinitis patients obtained during the autumn pollen season in Baotou (grassland city) and Beijing (non-grassland city), China.

Methods: Questionnaire surveys and allergen testing were conducted on 1170 and 1232 patients with chronic rhinitis visiting the Second Affiliated Hospital of Baotou Medical College and Beijing Tongren Hospital, respectively, during the autumn pollen period. Information regarding medical history, severity of symptoms, and diagnosis and treatment was collected.

Results: More patients with moderate to severe chronic rhinitis and asthma (both, \( P < 0.001 \)) were present in Baotou than in Beijing. Mugwort was the most abundant allergen in both regions, but the number of patients sensitized to outdoor allergens in Baotou was higher than that in Beijing (\( P < 0.001 \)). Indoor allergens in Beijing represented a considerable proportion of allergens, especially dust mites (33.4%). For patients with allergic rhinitis, nasal congestion, nasal itching, and runny nose were more severe in Baotou than in Beijing (\( P < 0.001 \)). In both Baotou and Beijing, allergy (\( P < 0.001 \) vs. \( P = 0.004 \)) and combined asthma (\( P = 0.049 \) vs. \( P = 0.005 \)) were common factors affecting the severity of the clinical symptoms chronic rhinitis. In Baotou, age (\( r_s = 0.195, P < 0.001 \)) and family allergy history (\( P = 0.010 \)) were also associated with symptom severity. Although significantly more patients in Baotou received oral antihistamines, nasal corticosteroids, and surgical treatment than in Beijing (\( P < 0.001 \)), the number of people receiving allergy immunotherapy in Baotou was lower (\( P = 0.004 \)) and post-treatment symptom control was worse (\( P < 0.001 \)) than that in Beijing.

Conclusions: During the pollen period, there were significant differences in the allergen spectrum between Baotou and Beijing. Allergy and combined asthma were common factors affecting the severity of clinical symptoms. Patients in Baotou presented with more severe clinical symptoms that were not satisfactorily managed due to the impact of pollen exposure, inconsistent access to care, and differing treatment modalities.

*Correspondence: summer_zhang1211@139.com; dr.luozhang@139.com
†Xu Xu and Long Qin contributed equally to this work
2 Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, No. 17, Hou Gou Hu Tong, Dong Cheng District, 100005 Beijing, People’s Republic of China
Full list of author information is available at the end of the article

© The Author(s) 2021. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction

Chronic rhinitis (CR) is a common inflammatory disease of the nasal mucosa. Its clinical manifestations include nasal congestion, nasal itching, runny nose, and sneezing. It is estimated that CR affects about 30% of the global population and causes a significant social and economic burden [1]. Clinically, CR is categorized as allergic rhinitis (AR) and non-AR (NAR) based on the etiology. Patients with AR and NAR often show similar nasal symptoms, and the difference is based on the result of allergen sensitization.

AR is a global health problem that affects 10–40% of the population worldwide, causing major illness and disability [2, 3]. A longitudinal study from 18 major cities in China showed that the self-reported prevalence of AR in adults increased by 6.5% in 6 years [4]. Mugwort and house dust mites are the two most commonly inhaled allergens in Asia [5]. In North China, more than 50% of individuals with respiratory allergy are allergic to Artemisia pollen [6]. Zhang et al. [7] showed that there is a strong correlation between the pollen concentration in the ambient air and the number of AR diagnoses and treatment. Epidemiological studies have shown that the prevalence of AR presents significant regional differences due to regional environmental and climatic conditions [8]. The incidence of AR in grassland areas was significantly higher than that in non-grassland areas. In China, the average self-reported prevalence of AR in adults is 17.6%; in Beijing, this prevalence is 20.2% [4]. In contrast, the AR prevalence in grassland areas can be as high as 32.4% based on epidemiological data and 18.5% based on allergen screening [8]. As a representative of the Eurasian grassland, the Inner Mongolia grassland is characterized by an abundance of pollen and diverse species; the high local prevalence of AR is attributed to climatic and environmental factors, particularly the large amount of pollen exposure [8–10]. Thus far, no studies have examined the influence of pollen exposure on the clinical characteristics of local patients with CR, particularly the symptom severity and quality of life associated with varying intensities of pollen exposure.

Baotou and Beijing are both cities in North China. Baotou is a grassland area located in the central and western part of the Inner Mongolian Autonomous Region, while Beijing is a non-grassland city. These cities represent evident environmental differences in climatic variables, airborne pollen allergen intensity and period of exposure. Moreover, as the capital of China, Beijing is more developed than Baotou (third-tier city) in terms of the economy and medical level. The purpose of this study was to compare the clinical profiles of patients with CR during the autumn pollen season in Baotou and Beijing. We intended to elucidate the influence of differences in pollen allergen intensity and exposure period on the disease severity. We also investigated the differences in treatment status for these patients to help set up an effective allergy management strategy in the studied regions.

Methods

Study region

This study was jointly conducted by the Second Affiliated Hospital of Baotou Medical College in Inner Mongolia Autonomous Region, China and the Beijing Tongren Hospital in Beijing, China. We continuously included outpatients who volunteered to participate in the survey during the autumn pollen period of 2019 in both regions. Patients were eligible to join the study if they meet the following criteria: (1) age 18–60 years; (2) permanent resident of the Baotou or Beijing areas (lived in the region for more than half a year); (3) experienced two or more nasal symptoms (nasal congestion, nasal itching, runny nose, sneezing) in the past year; and (4) had received oral antihistamines, nasal corticosteroids, surgery, allergy immunotherapy or other treatments (oral hormones, antibiotics, mucus promoting agents, nasal irrigation, etc.) for nasal symptoms. We collected the serum samples and conducted allergen testing when the participants visited the hospital for treatment during the autumn pollen period; the participants completed the questionnaire survey at the same time. The diagnosis of AR was based on the latest AR episode and its impact on asthma (Allergic Rhinitis and its Impact on Asthma, ARIA) [3]. AR was confirmed by the presence of symptoms induced by exposure to an allergen shown to produce a serum allergen specific-IgE (sIgE), and the remaining patients were diagnosed with NAR.

Under the guidance of specialist doctors and nurses, a questionnaire survey was conducted in both regions. The questionnaire has been provided in an additional file [see Additional file 1]. The information collected included basic demographics (age and sex), severity of nasal symptoms in the past year, incidence of combined asthma, family history of allergies, smoking history, impact of rhinitis on life in the past year, and all previous medical history.

The prevalence of AR and NAR in rural areas in northern China is reported to be 16.78% and 24.60%,
Selection of the autumn pollen season
For each area, the pollen population shows a constant pattern of seasonal changes. Based on data describing the total pollen concentration in the environment provided by the Baotou and Beijing Meteorological Bureaus, the start of pollen season was defined when the pollen count was 5 pollen grains/m³ per day for more than 3 consecutive days, while the end of pollen season was defined when the pollen count fell to <10 pollen grains/m³ per day for more than 3 consecutive days [13].

When evaluating the factors affecting the clinical symptoms of the patients in the two regions, a Spearman correlation analysis was performed on the continuous variable indicators of non-normal distribution, and the Mann–Whitney U test was used to compare the allergen profiles of patients with AR in the two regions. The Mann–Whitney U test was used to analyze the difference in the severity of clinical symptoms between the AR population and the NAR population in the two regions. When evaluating the factors affecting the clinical symptoms of the patients in the two regions, a Spearman correlation analysis was performed on the continuous variable indicators of non-normal distribution, and the Mann–Whitney U test was used for the remaining binary variables. The chi-square test was used to compare the diagnosis and treatment of patients with CR in the two regions. A P-value of <0.05 was considered statistically significant.

Results
Demographic and clinical characteristics
This study recruited patients with CR who were eligible for enrollment during the pollen period in two regions in 2019, including 1170 individuals in Baotou and 1232 in Beijing. The demographic and clinical characteristics of the patients enrolled in the two regions are shown in
Table 1. There were no significant differences between the patients in the two regions in terms of age or sex. The number of patients with a disease course of <1 year was significantly greater in Baotou than that in Beijing, and the number of patients with a disease course of 6–10 years was higher in Beijing than in Baotou ($P < 0.001$). The number of patients with intermittent and persistent CR was similar in Beijing, while intermittent CR was the dominant type in Baotou (accounting for 74.2%), with the number of these patients being significantly higher in Baotou than in Beijing (74.2% vs. 46.7%, $P < 0.001$). The number of patients with intermittent and persistent CR was similar in Beijing, while intermittent CR was the dominant type in Baotou (accounting for 74.2%), with the number of these patients being significantly higher in Baotou than in Beijing (74.2% vs. 46.7%, $P < 0.001$). The number of patients with intermittent CR was significantly greater in Baotou than that in Beijing, while intermittent CR was the dominant type in Baotou (accounting for 74.2%), with the number of these patients being significantly higher in Baotou than in Beijing (74.2% vs. 46.7%, $P < 0.001$). The number of patients with intermittent and persistent CR was similar in Beijing, while intermittent CR was the dominant type in Baotou (accounting for 74.2%), with the number of these patients being significantly higher in Baotou than in Beijing (74.2% vs. 46.7%, $P < 0.001$). 

Allergen spectrum

Allergen testing was performed on all the participants in the two regions to define the allergen spectrum (Fig. 1) and major allergens (Fig. 2) of patients with AR in the two regions. Among the 10 most common allergens tested, mugwort was the predominant allergen in the pollen period for both regions. In Baotou, outdoor allergens (trees, mugwort, ragweed, and humulus) were the main allergens during the pollen period. In Beijing, dust mites also accounted for a considerable proportion allergens, and became the second largest allergen after mugwort. More patients were allergic to trees ($P < 0.001$), mugwort ($P < 0.001$), and cat hair ($P < 0.01$) in Baotou than in Beijing, while more patients were allergic to cockroaches ($P < 0.05$), house dust ($P < 0.01$), and dust mites ($P < 0.001$) in Beijing.

Analysis of severity of clinical symptoms and risk factors

We categorized the presence and severity of the four nasal symptoms (nasal blockage, nasal itching, runny nose, and sneezing) as none, mild, moderate, or severe, and subsequently compared the severity of the clinical symptoms of the AR and NAR populations in the two regions (Fig. 3). Among the AR population, the number of patients with the four symptoms scored as “severe” was higher in Baotou than that in Beijing. Among them, the symptoms of nasal congestion, nasal itching, and runny nose were more frequent ($P < 0.001$). Patients were more frequently categorized as having “mild to moderate” symptoms in Beijing compared to those in Baotou. This phenomenon was not observed among the NAR population.

We also analyzed the risk factors for the severity of clinical symptoms in both regions (Table 2). Allergy and combined asthma were common risk factors affecting the severity of clinical symptoms in the two regions.

Table 1  Demographic and clinical characteristics of the study population

| Characteristic                        | Baotou (N = 1170) | Beijing (N = 1232) | $P$-value |
|---------------------------------------|------------------|--------------------|-----------|
| Age (years), median (IQR)             | 33.0 (25.0–47.0) | 32.0 (28.0–37.0)   | 0.097     |
| Sex (male/female), n (%)              | 584 (49.9%)/586 (50.1%) | 614 (49.8%)/618 (50.2%) | 0.970     |
| Course of disease, n (%)              |                  |                    | $<0.001$ |
| < 1 year                              | 328 (28.0%)      | 221 (18.0%)        |           |
| 1–5 year                              | 571 (48.8%)      | 636 (51.6%)        |           |
| 6–10 year                             | 190 (16.2%)      | 269 (21.8%)        |           |
| > 10 year                             | 81 (6.9%)        | 106 (8.6%)         |           |
| Persistent/intermittent, n (%)        | 302 (25.8%)/868 (74.2%) | 657 (53.3%)/575 (46.7%) | $<0.001$ |
| Mild/moderate to severe, n (%)        | 96 (8.2%)/1074 (91.8%) | 223 (18.1%)/1009 (81.9%) | $<0.001$ |
| Allergen, n (%)                       |                  |                    |           |
| Positive/negative                     | 721 (61.6%)/449 (34.8%) | 808 (65.6%)/424 (34.4%) | 0.044     |
| Outdoor allergens/indoor allergens    | 648 (89.9%)/301 (41.7%) | 610 (75.5%)/470 (58.2%) | $<0.001$ |
| With asthma, n (%)                    | 158 (13.5%)      | 89 (7.2%)          | $<0.001$ |
| TNSS, median (IQR)                    | 8.0 (4.0–12.0)   | 8.0 (6.0–9.0)      | $<0.001$ |

Descriptive statistics were used to study population characteristics and general information. Non-normally distributed continuous variables were described using the interquartile range, and Mann–Whitney U test and Chi-square test were performed to analyze the differences in clinical characteristics between Baotou and Beijing. TNSS: total nasal symptom score. $P < 0.05$ is shown in bold.
In addition, for patients with CR in Baotou, age ($r_s = 0.195, P < 0.001$) and family history of allergies ($P = 0.010$) were also associated with the severity of clinical symptoms.

**Treatment status**

We determined the treatment status of patients with CR in the two regions that received a diagnosis and treatment for their nasal symptoms (Table 3). In Baotou, the number of patients treated with oral antihistamines (32.6% vs. 25.3%, $P < 0.001$), nasal corticosteroids (33.9 vs. 18.4%, $P < 0.001$), and surgery (39.3 vs. 4.4%, $P < 0.001$) was significantly higher than that in Beijing, while in Beijing, more patients chose allergy immunotherapy (1.3 vs. 0.3%, $P = 0.004$) and other treatment (58.9 vs. 46.9%, $P < 0.001$) options. Although most patients with CR in
Fig. 3  Comparison of severity of clinical symptoms between AR and NAR populations in Baotou and Beijing. The Mann–Whitney U test was used to analyze the difference in the severity of clinical symptoms between the AR and NAR population in the two regions. AR Allergic rhinitis, NAR nonallergic rhinitis. **P < 0.01, ***P < 0.001
Baotou were treated with oral antihistamines, nasal corticosteroids, and/or surgery, the symptom control after treatment was significantly worse than that in Beijing (50% vs. 77.4%, \( P < 0.001 \)). In addition, 45.7% of patients with CR in Baotou had not visited a hospital in the past year, which was much a higher proportion than that in Beijing, where 86.3% of patients had 1–5 hospital visits per year (\( P < 0.001 \)).

**Discussion**

CR is a common upper respiratory tract disease that can occur at the same time as other respiratory diseases and causes considerable economic and social burden [1]. As one of the most common diseases, AR has received considerable research interest globally, and NAR also affects about 200 million people worldwide [17, 18]. Pollen produced by gramineous plants is currently listed as the main air allergen. Studies conducted around the world have emphasized that differences in climate and environment will affect the concentration of pollen in the air, which has a major impact on allergic diseases [19]. This study collected clinical information on the autumn pollen exposure of CR patients in Baotou and Beijing, and compared and analyzed the differences in the clinical status of CR in the two regions, which provides significant reference for guiding the clinical treatment and intervention of patients with CR.

Our research shows that there were significant differences in the allergen spectrum between the Baotou and Beijing regions. This difference was closely related to differences in the environmental conditions between the two regions. Inner Mongolia has the largest grassland area in China. Compared with the Beijing, pollen species are more abundant and exposure is greater in Baotou [20, 21]. A cross-sectional study by Li et al. [22] showed that in Chinese patients with asthma and/or rhinitis, house dust mites are the most common air allergen. In areas with long and cold winters, the incidence of house dust mite allergy is lower [23–25]. Inner Mongolia is located at a higher latitude than Beijing, and it has large day vs. night temperature difference. The average temperature in winter is approximately \(-28 \, ^\circ \text{C}\) and the season can last for almost 6 months, which is not conducive to the growth and spread of house dust mites.

Among the AR population, the clinical symptoms of patients in Baotou area were more severe than those in Beijing. However, these differences were not observed in the NAR population. This may be due to the different etiologies of AR and NAR and the varying degrees of pollen exposure during the pollen season in the two regions. While mugwort pollen is the most important allergen for patients with AR in the pollen season for both regions, AR is an IgE-mediated type 1 allergic inflammation dominated by a type 2 immune response.

### Table 2

Analysis of related factors on the severity of clinical symptoms of chronic rhinitis patients in Baotou and Beijing

| Variable                        | Baotou | Beijing | \( r_s \) | \( P \)-value | \( r_s \) | \( P \)-value |
|---------------------------------|--------|---------|-----------|--------------|-----------|-------------|
| Age                             | 0.195  | \(< 0.001 \) | 0.009     | 0.766        |           |             |
| Sex                             | –      | 0.478   | –         | 0.514        | –         | 0.004       |
| Allergic or not                 | –      | \(< 0.001 \) | –         | \( 0.004 \)  | –         | 0.005       |
| Family history of allergy       | –      | 0.010   | –         | 0.990        | –         | 0.004       |
| Smoking history                 | –      | 0.062   | –         | 0.074        | –         | 0.005       |
| With asthma                     | –      | 0.049   | –         | 0.005        | –         | 0.005       |

A Spearman correlation analysis was performed on the continuous variable indicators of non-normal distribution (age), and the Mann–Whitney \( U \) test was used for the remaining binary variables in order to evaluate the factors affecting the clinical symptoms of patients in the two regions. \( P < 0.05 \) is shown in bold.

### Table 3

Comparison of diagnosis and treatment of patients with chronic rhinitis in Baotou and Beijing

| Treatment                        | Baotou \((N = 1170)\) | Beijing \((N = 1232)\) | \( P \)-value |
|----------------------------------|------------------------|------------------------|--------------|
| Oral antihistamines              | 381 (32.6%)            | 312 (25.3%)            | \(< 0.001 \) |
| Nasal corticosteroids            | 397 (33.9%)            | 227 (18.4%)            | \(< 0.001 \) |
| Surgical treatments              | 460 (39.3%)            | 54 (4.4%)              | \(< 0.001 \) |
| Allergy immunotherapy            | 3 (0.3%)               | 16 (1.3%)              | 0.004        |
| Other treatments                 | 549 (46.9%)            | 726 (58.9%)            | \(< 0.001 \) |
| Symptoms controlled/uncontrolled after treatment | 585 (50.5%)/585 (50%) | 954 (77.4%)/278 (22.6%) | \(< 0.001 \) |
| Number of visits in the past year (times/year), n (%) | 535 (45.7%) | 110 (8.9%) | \(< 0.001 \) |
| 0                                |                        |                        |              |
| 1–5                              | 576 (49.2%)            | 1063 (86.3%)           |              |
| 6–10                             | 43 (3.7%)              | 47 (3.8%)              |              |
| > 10                             | 16 (1.4%)              | 12 (1.0%)              |              |

The chi-square test was used to compare the diagnoses and treatment of patients with chronic rhinitis in the two regions. \( P < 0.05 \) is shown in bold.
than in Beijing. are significantly more individuals with asthma in Baotou asthma in northern China [6] and may explain why there In addition, Artemisia pollen allergy is the main cause of with asthma tend to have more severe clinical symptoms. the focus of our future work. attention to the impact of environmental factors will be exhibited by patients with AR in Baotou when compared with those of patients in Beijing. Notably, although the major factor differentially affecting AR in grassland and non-grassland areas is allergen availability, epidemiological studies have shown that environmental triggers including risk factors (e.g., pollution) are considered major contributors to the dramatic increase in the incidence and the prevalence of allergic diseases, and the influence of these environmental factors is believed to be mediated by epigenetic mechanisms [28, 29]. Therefore, paying more attention to the impact of environmental factors will be the focus of our future work.

This study also analyzed the relevant factors affecting the severity of the overall clinical symptoms of patients with CR in the two regions; allergy and concomitant asthma were common risk factors for CR in both regions. AR and asthma often coexist as a combined airway disease [30]. Most patients with asthma experience symptoms of allergic inflammation in the airways. IgE plays a central role in the pathogenesis of various allergic diseases including asthma and AR [31, 32]; thus, patients with asthma tend to have more severe clinical symptoms. In addition, Artemisia pollen allergy is the main cause of asthma in northern China [6] and may explain why there are significantly more individuals with asthma in Baotou than in Beijing.

There were significant differences in the diagnosis, treatment, and symptom control of patients with CR in the two regions, due to the differing socioeconomic status and medical level. On one hand, this may be attributed to the more severe clinical symptoms exhibited by patients with AR in Baotou. However, compared with those in Beijing, the government’s medical resources in Baotou are limited, which coexists with patients’ lack of awareness of the disease and poor patient compliance. In addition, allergen immunotherapy is currently the only therapeutic approach recommended by the World Health Organization that targets the cause of the disease and produces long-term effects through immune regulatory mechanisms [33]. Our findings showed that the number of patients receiving allergy immunotherapy in Baotou was significantly lower than that in Beijing, which was also associated with the prognosis of the disease. In Baotou, no corresponding allergy immunotherapy is currently being carried out for CR, and a small number of patients receive immunotherapy in hospitals in Beijing or other cities. Currently, immunotherapy is only available for use against dust mites in China. In Baotou, which is a representative grassland city, pollen is the most important allergen for the AR population. Therefore, more vigorous development of pollen allergen-specific immunotherapy is required in grassland cities for better long-term curative effects.

This study has its limitations. First, the Second Affiliated Hospital of Baotou Medical College and Beijing Tongren Hospital are both large-scale tertiary general hospitals, and most patients who visit these hospitals for treatment are urban residents. Access to care between urban and rural residents remains inconsistent. Second, we only included adult patients with CR in the study; pediatric patients were not included. Finally, in this study, we adopted the traditional standard for the sIgE antibody threshold, i.e., 0.35 kUA/L, to identify participants with a clinically evident allergic disease [15]. Although recent consensus guidance recommended that all clinical laboratories should report sIgE results as analytical measurements based on the accepted lower limit of quantitation of the assay [34], scholars have also emphasized that sIgE levels between 0.1 and 0.35 kUA/L should be cautiously interpreted, combined with the clinical symptoms after allergen exposure, because the clinical significance of the threshold remains ambiguous [35]. The proportion of patients with sIgE levels of 0.1–0.35 kUA/L in the pollen season collected in this study is extremely small, which may be related to the high exposure intensity of pollen in this period. Further research focusing on the correlation between sIgE levels lower than 0.35 kUA/L and the clinical symptoms in other periods, such as the winter season, is required. Future studies including a larger sample size and more detailed stratified sampling methods, especially including children, are required to further elucidate how pollen distribution and environmental factors contribute to the intensity of disease-related sensitization in order to develop more effective CR control strategies for different vegetation areas in North China.
Conclusions
This study revealed differences in CR epidemiology between two regions in China by comparing and analyzing the status of patients with CR during the autumn pollen exposure period in Baotou and Beijing. There were significant differences in the allergen spectrum in the two cities. Allergy and combined asthma were common risk factors affecting the severity of clinical symptoms in the two regions. Compared with Beijing, patients with AR in Baotou present with more severe clinical symptoms that are not satisfactorily controlled due to the impact of pollen exposure and socio-economic and medical levels in the area.

Abbreviations
CR: Chronic rhinitis; AR: Allergic rhinitis; NAR: Non-AR; ARIA: Allergic Rhinitis and its Impact on Asthma; sIgE: Specific-IgE; TNSS: Total nasal symptom score; PiAR: Pollen-induced AR.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13223-021-00591-w.

Acknowledgements
Not applicable.

Authors’ contributions
All the authors contributed significantly to the study: QL, RL and ZY collected the data. XX and ZY wrote the manuscript. WC and ZL designed and supervised the study. All authors read and approved the final manuscript.

Funding
This work was supported by grants from the national key R&D program of China (2016YFC0902003), the program for the Changjiang scholars and innovative research team (IRT13082), the national natural science foundation of China (81630022 and 82071022), Beijing Municipal Science and Technology Project (Z181100001618002) and Beijing talents foundation (20180000212232K14).

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Declarations
Ethics approval and consent to participate
The study was approved by the medical ethics committee of Beijing TongRen Hospital and the Second Affiliated Hospital of Baotou Medical College, and written informed consent was obtained from each patient before participation.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Otolaryngology Head and Neck Surgery, Beijing Tong Ren Hospital, Capital Medical University, Beijing, China. 2Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, No. 17, Hou Gou Hu Tong, Dong Cheng District, 100005 Beijing, People’s Republic of China. 3Department of Allergy, Beijing Tong Ren Hospital, Capital Medical University, Beijing, China. 4The Second Affiliated Hospital of Baotou Medical College, Baotou Medical College, Baotou, China.

Received: 9 June 2021 Accepted: 24 August 2021
Published online: 11 October 2021

References
1. Meng Y, Lou H, Wang Y, Wang X, Cao F, Wang K, et al. Endotypes of chronic rhinitis: a cluster analysis study. Allergy. 2019;74:720–30.
2. Bousquet J, Khaltava N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8–160.
3. Brozek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140:950–8.
4. Wang XD, Zheng M, Lou HF, Wang CS, Zhang Y, Bo MY, et al. An increased prevalence of self-reported allergic rhinitis in major Chinese cities from 2005 to 2011. Allergy. 2016;71:1170–80.
5. Duan S, Zhao L, Zhang Y, Zhang N, Zheng M, Wang Q, et al. Tropomyosin in mugwort cross-reacts to house dust mite, eliciting non-Th2 response in allergic rhinitis patients sensitized to house dust mite. Clin Mol Allergy. 2021;19:2.
6. Gao Z, Fu WY, Sun Y, Gao B, Wang HY, Liu M, et al. Artemisia pollen allergy in China: Component-resolved diagnosis reveals allergic asthma patients have significant multiple allergen sensitization. Allergy. 2019;74:284–93.
7. Zhang F, Krafft T, Zhang D, Xu J, Wang W. The association between daily outpatient visits for allergic rhinitis and pollen levels in Beijing. Sci Total Environ. 2012;417–418:39–44.
8. Wang XY, Ma TT, Wang XY, Zhuang Y, Wang XD, Ning HY, et al. Prevalence of pollen-induced allergic rhinitis with high pollen exposure in grasslands of northern China. Allergy. 2018;73:1232–43.
9. Ma TT, Zhuang Y, Shi HY, Ning HY, Guo MY, He H, et al. Epidemiology of allergic rhinitis in children in grassland of Baotou. Zhonghua Er Bi Yan Hou Jing Wai Ke Za Zhi. 2019;54:571–5.
10. Ma T, Zhuang Y, Wang H, Wei Q, Shi H, Ning H, et al. Analysis of sensitization characteristics of artemisia pollen in the Baotou grassland region of China. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2020;34:1092–6.
11. Huang Y, Zhang Y, Zhang L. Prevalence of allergic and nonallergic rhinitis in a rural area of northern China based on sensitization to specific aeroallergens. Allergy Asthma Clin Immunol. 2018;14:77.
12. Deng ZY, Liu XJ, Sa RN, Xu HX, Fu Q, Xu DY, et al. Epidemiological investigation of allergic rhinitis in central cities and countrysides of Inner Mongolia region. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2021;56:635–42.
13. Huang Y, Wang C, Zhang Y, Zhang L. Developing nomograms for identifying allergic rhinitis among chronic rhinitis: a real-world study. World Allergy Organ J. 2021;14:100534.
14. Bateman ED, Hurud SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald JM, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31:143–78.
15. Pastorello EA, Incorvaia C, Pravettoni V, Bonini S, Canonica GW, Ortolani C, et al. A multicentric study on sensitivity and specificity of a new in vitro test for measurement of IgE antibodies. Ann Allergy. 1991;67:365–70.
16. Okubo K, Suzuki T, Tanaka A, Aoki H. Long-term safety and efficacy of rupatidine in Japanese patients with perennial allergic rhinitis: a 52-week open-label clinical trial. J Drug Assess. 2019;8:104–14.
17. Greiner AN, Hellings PW, Rotiroti G, Scadding GK. Allergic rhinitis. Lancet. 2011;378:2112–22.
18. Hellings PW, Klimek L, Cingi C, Agache I, Akdis C, Bachert C, et al. Non-allergic rhinitis: position paper of the European academy of allergy and clinical immunology. Allergy. 2017;72:1657–65.
19. García-Mozo H. Poaceae pollen as the leading aeroallergen worldwide: a review. Allergy. 2017;72:1849–58.
20. Lan Z, Bai Y. Testing mechanisms of N-enrichment-induced species loss in a semiarid Baotou grassland: critical thresholds and implications for long-term ecosystem responses. Philos Trans R Soc Lond B Biol Sci. 2012;367:3125–34.
21. Lu N, Wilkie B, Ni J, John R, Chen J. Climate change in Baotou from 1955 to 2005—trends at regional, biome and local scales. Environ Res Lett. 2009;4:045006.
22. Li J, Sun B, Huang Y, Lin X, Zhao D, Tan G, et al. A multicentre study assessing the prevalence of sensitizations in patients with asthma and/or rhinitis in China. Allergy. 2009;64:1083–92.
23. Munir AK, Kjellman NI, Björkstén B. Exposure to indoor allergens in early infancy and sensitization. J Allergy Clin Immunol. 1997;100:177–81.
24. Rönmark E, Perzanowski M, Platts-Mills T, Lundbäck B. Different sensitization profile for asthma, rhinitis, and eczema among 7-8-year-old children: report from the Obstructive Lung Disease in Northern Sweden studies. Pediatr Allergy Immunol. 2003;14:91–9.
25. Munir AK. Mite sensitization in the Scandinavian countries and factors influencing exposure levels. Allergy. 1998;53:64–70.
26. Daramola OO, Kern RC. An update regarding the treatment of nonallergic rhinitis. Curr Opin Otolaryngol Head Neck Surg. 2016;24:10–4.
27. Hoshino T, Hoshino A, Nishino J. Relationship between environment factors and the number of outpatient visits at a clinic for nonallergic rhinitis in Japan, extracted from electronic medical records. Eur J Med Res. 2015;20:60.
28. Acevedo N, Alashkar Alhamwe B, Caraballos L, Ding M, Ferrante A, Garn H, et al. Perinatal and Early-Life Nutrition, Epigenetics, and Allergy. Nutrients. 2021;13:724.
29. Potaczek DP, Harb H, Michel S, Alhamwe BA, Renz H, Tost J. Epigenetics and allergy: from basic mechanisms to clinical applications. Epigenomics. 2017;9:539–71.
30. Khan DA. Allergic rhinitis and asthma: epidemiology and common pathophysiology. Allergy Asthma Proc. 2014;35:537–61.
31. Fallon PG, Schwartz C. The high and lows of type 2 asthma and mouse models. J Allergy Clin Immunol. 2020;145:496–8.
32. Humbert M, Bousquet J, Bachert C, Palomares O, Pfister P, Kottakis I, et al. IgE-mediated multimorbidities in allergic asthma and the potential for omalizumab therapy. J Allergy Clin Immunol Pract. 2019;7:1418–29.
33. Biagtan M, Viswanathan R, Bush RK. Immunotherapy for house dust mite sensitivity: where are the knowledge gaps? Curr Allergy Asthma Rep. 2014;14:482.
34. Hamilton RG. Clinical laboratories worldwide need to report IgE antibody results on clinical specimens as analytical results and not use differential positive thresholds. J Allergy Clin Immunol. 2015;136:811–2.
35. Linden CC, Misra RT, Wegienka G, Havstad S, Ownby DR, Johnson CC, et al. Analysis of allergen specific IgE cut points to cat and dog in the Childhood Allergy Study. Ann Allergy Asthma Immunol. 2011;106:153-8. e2.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.